{"id":"NCT02437318","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.","officialTitle":"A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-23","primaryCompletion":"2018-06-12","completion":"2023-06-09","firstPosted":"2015-05-07","resultsPosted":"2019-08-13","lastUpdate":"2025-02-13"},"enrollment":572,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Fulvestrant","otherNames":[]},{"type":"DRUG","name":"Alpelisib","otherNames":["BYL719"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fulvestrant + alpelisib","type":"EXPERIMENTAL"},{"label":"Fulvestrant + placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To determine whether treatment with alpelisib plus fulvestrant prolonged progression-free survival (PFS) compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 (HER2)-negative advanced breast cancer, who received prior treatment with an aromatase Inhibitor (AI) either as (neo)adjuvant or for advanced disease.","primaryOutcome":{"measure":"Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort","timeFrame":"Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months","effectByArm":[{"arm":"PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant","deltaMin":11,"sd":null},{"arm":"PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant","deltaMin":5.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00065"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":10},"locations":{"siteCount":197,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","Czechia","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Lebanon","Mexico","Netherlands","Peru","Romania","Russia","South Korea","Spain","Sweden","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["39177931","38439079","33780274","33246021","32416251","31091374"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":110,"n":284},"commonTop":["Diarrhoea","Hyperglycaemia","Nausea","Decreased appetite","Fatigue"]}}